Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

SYDNEY, Oct. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company developing innovative therapies for brain cancers, today announced its participation in a fully funded Australian Medical Research Future Fund (MRFF) project titled "Sequential & Temporal Therapeutic Agility for the Treatment of Diffuse Midline Glioma (DMG)".

Read more at prnewswire.com